ACR (American College of Rheumatology) is a society covering all immune-related diseases, and este año's conferencia is programado to be celebrado en the San Diego Convention Center from November 10 to 15.
This poster presentación will feature resultados preclínicos for an osteoartritis pain-inhibiting compuesto, part of RudaCure's RCI002 proyecto currently under desarrollo. The resultados to be presentó demonstrate pain suppression for up to two weeks following a single administration.
Through formulación investigación, this compuesto se espera que be applicable not only for osteoartritis but also for degenerative disc disease (cervical and lumbar spine, etc.) with administration once every six months or once a year.
